These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. No gain, no pain: NaV1.7 as an analgesic target. King GF; Vetter I ACS Chem Neurosci; 2014 Sep; 5(9):749-51. PubMed ID: 25111714 [TBL] [Abstract][Full Text] [Related]
3. [Pain and analgesia : Mutations of voltage-gated sodium channels]. Eberhardt MJ; Leffler A Schmerz; 2017 Feb; 31(1):14-22. PubMed ID: 27402262 [TBL] [Abstract][Full Text] [Related]
4. Human Mendelian pain disorders: a key to discovery and validation of novel analgesics. Goldberg YP; Pimstone SN; Namdari R; Price N; Cohen C; Sherrington RP; Hayden MR Clin Genet; 2012 Oct; 82(4):367-73. PubMed ID: 22845492 [TBL] [Abstract][Full Text] [Related]
5. Bilateral congenital corneal anesthesia in a patient with SCN9A mutation, confirmed primary erythromelalgia, and paroxysmal extreme pain disorder. Kim DT; Rossignol E; Najem K; Ospina LH J AAPOS; 2015 Oct; 19(5):478-9. PubMed ID: 26486037 [TBL] [Abstract][Full Text] [Related]
6. Insensitivity to Pain upon Adult-Onset Deletion of Nav1.7 or Its Blockade with Selective Inhibitors. Shields SD; Deng L; Reese RM; Dourado M; Tao J; Foreman O; Chang JH; Hackos DH J Neurosci; 2018 Nov; 38(47):10180-10201. PubMed ID: 30301756 [TBL] [Abstract][Full Text] [Related]
7. What are the treatment options for paroxysmal extreme pain disorder? Suter MR Pain Manag; 2015; 5(4):229-32. PubMed ID: 26059255 [No Abstract] [Full Text] [Related]
13. Nav1.7 is essential for nociceptor action potentials in the mouse in a manner independent of endogenous opioids. Deng L; Dourado M; Reese RM; Huang K; Shields SD; Stark KL; Maksymetz J; Lin H; Kaminker JS; Jung M; Foreman O; Tao J; Ngu H; Joseph V; Roose-Girma M; Tam L; Lardell S; Orrhult LS; Karila P; Allard J; Hackos DH Neuron; 2023 Sep; 111(17):2642-2659.e13. PubMed ID: 37352856 [TBL] [Abstract][Full Text] [Related]
14. Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile. McDonnell A; Schulman B; Ali Z; Dib-Hajj SD; Brock F; Cobain S; Mainka T; Vollert J; Tarabar S; Waxman SG Brain; 2016 Apr; 139(Pt 4):1052-65. PubMed ID: 26920677 [TBL] [Abstract][Full Text] [Related]
15. Analgesic effect of Botulinum toxin in neuropathic pain is sodium channel independent. Kesdoğan AB; Neureiter A; Gaebler AJ; Kalia AK; Körner J; Lampert A Neuropharmacology; 2024 Aug; 253():109967. PubMed ID: 38657946 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of a rat Nav1.7 loss-of-function model with insensitivity to pain. Chen L; Effraim PR; Carrara J; Zhao P; Dib-Hajj FB; Dib-Hajj SD; Waxman SG Pain; 2020 Jun; 161(6):1350-1360. PubMed ID: 31977939 [TBL] [Abstract][Full Text] [Related]
17. Mapping protein interactions of sodium channel Na Kanellopoulos AH; Koenig J; Huang H; Pyrski M; Millet Q; Lolignier S; Morohashi T; Gossage SJ; Jay M; Linley JE; Baskozos G; Kessler BM; Cox JJ; Dolphin AC; Zufall F; Wood JN; Zhao J EMBO J; 2018 Feb; 37(3):427-445. PubMed ID: 29335280 [TBL] [Abstract][Full Text] [Related]
18. Sodium channel Nav1.7 in vascular myocytes, endothelium, and innervating axons in human skin. Rice FL; Albrecht PJ; Wymer JP; Black JA; Merkies IS; Faber CG; Waxman SG Mol Pain; 2015 May; 11():26. PubMed ID: 25957174 [TBL] [Abstract][Full Text] [Related]
19. Diversity of composition and function of sodium channels in peripheral sensory neurons. Dib-Hajj SD; Waxman SG Pain; 2015 Dec; 156(12):2406-7. PubMed ID: 26580678 [No Abstract] [Full Text] [Related]
20. Locus revealed: Painlessness via loss of Na Simonetti M; Kuner R Neuron; 2021 May; 109(9):1413-1416. PubMed ID: 33957067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]